Stockreport

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

Agios Pharmaceuticals, Inc.  (AGIO) 
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.agios.com/investor-overview
PDF – Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Vorasidenib; Agios to Shar [Read more]